Rockwell Medical, Inc. · NASDAQ:RMTI
Rockwell Medical — Q2 2020 Earnings Presentation
25 slides from Rockwell Medical's earnings presentation, Aug 10, 2020
Slide 1: Q2 2020 Financial Results and Business Update
Q2 2020 Financial Results and Business Update August 10, 2020 1
Slide 2: Call Participants
Call Participants Russell Ellison, M.D., M.Sc. President and Chief Executive Officer Tim Chole Vice President of Marketing Paul McGarry VP, Corporate Controller and Principal Accounting Officer Marc Hoffman, M.D. Chief Medical Officer 2
Slide 3: Forward-Looking Statements
Forward-Looking Statements Certain statements in this press release may constitute “forward-looking statements” within the meaning of the federal securities laws, including, but not limited to, the impact of COVID-19 on Rockwell Medical’s business and operations, the commercialization of Triferic Di
Slide 4: Today's Call
Today’s Call 1 Our Commitment to Hemodialysis 2 Triferic® Dialysate 3 Triferic® AVNUTM 4 New Indication Opportunities 5 Q2 Financial Update 6 Q&A 4
Slide 5: Our Mission and Vision
Our Mission and Vision Mission: Transform the treatment of iron deficiency and anemia around the world to improve outcomes for patients Continue to develop into a more medically- and scientifically-driven company Vision: Drive next phase of growth by leveraging the attributes of our ferric pyrophosp
Slide 6: Our Commitment to the Hemodialysis Community
Our Commitment to the Hemodialysis Community Concentrates Business Triferic Platform • #2 supplier of dialysis concentrates products in • Two FDA-approved products: Triferic Dialysate the U.S. and Triferic AVNU • $60+ million of annualized sales • Only FDA-approved therapies indicated to • Facilitat
Slide 7: COVID-19 Commentary
COVID-19 Commentary • COVID-19 has had a unique impact on the dialysis community in the U.S. • Rockwell Medical stands with the dialysis community and we continue our efforts to maintain our high level of service – Employee safety initiatives – Enhanced sanitization protocols in manufacturing facili
Slide 8: Q2 2020 Highlights
Q2 2020 Highlights (©ROCKWELL
Slide 9: Q2 2020 Highlights
Q2 2020 Highlights • Net sales were $15.9 million • Triferic net sales were $0.2 million and $0.5 million for the three and six months ended June 30, 2020 • Nearly 2,800 contracted patients on therapy for Triferic Dialysate, representing >400,000 annualized treatments • Signed contracts with 12 addi
Slide 10: Triferic Dialysate Commercial Metrics
Triferic® Dialysate Commercial Metrics 10
Slide 11: Summary of Key Metrics
Summary of Key Metrics Metric 9/30/19 12/31/19 3/31/20 6/30/20 Contracted Patients on Therapy 1,000+ 1,650+ ~2,000 ~2,800 Contracted Annualized Treatment 150,000+ 250,000+ ~300,000 >400,000 U.S. Market Introduction Volume Evaluation Program Patients 1,300+ 600+ 2,250+ ~1,500 Evaluation Program Conve
Slide 12: Triferic: U.S. Market Introduction
Triferic: U.S. Market Introduction Contracted Clinics Evaluation Program Clinics 50 40 47 36 45 35 40 30 26 35 39 25 30 27 20 25 23 15 20 10 10 15 10 5 5 0 12/31/2019 3/31/2020 6/30/2020 0 12/31/2019 3/31/2020 6/30/2020 COVID-19 Impact* * Includes four clinics that were trained for administration an
Slide 13: Triferic AVNU
Triferic? AVNU (©ROCKWELL
Slide 14: Triferic AVNU Quarterly Overview
Triferic AVNU Quarterly Overview Expands U.S. access and provides more access to global markets heavily reliant on on-line bicarb generation • Triferic AVNU received FDA Approval on March 27, 2020 – Triferic AVNU joins Triferic Dialysate as the only FDA-approved products indicated to replace iron an
Slide 15: Real-World Data Update
Real-World Data Update (©ROCKWELL
Slide 16: Real-World Data: Overall Clinical Impact
Real-World Data: Overall Clinical Impact Additional data from USRDS on single clinic shows meaningful outcomes: Rates for all cause and infection-related hospitalization, and mortality for HHD patients, 2016-17* Infectious Deaths Year # of patient- Hospitalizations Inpatient days hospitalizations In
Slide 17: Preview of FPC New Indication Opportunities
Preview of FPC New Indication Opportunities 17
Slide 18: 1st priority: Home Infusion - Overview
1st priority: Home Infusion - Overview • Opportunity: I.V. administration of specialty drugs or nutrients in the home setting • Home and specialty infusion marketplace is experiencing explosive growth • Many patients treated with home infusion therapies suffer from iron deficiency anemia • Tradition
Slide 19: Home Infusion: Favorable Market Access and Rapid, Low Cost Clinical Program
Home Infusion: 1st priority Favorable Market Access and Rapid, Low Cost Clinical Program Market access conditions for FPC as a home infusion therapy are favorable: • Almost 50% of home infusion therapy is reimbursed by commercial payers using a well-established universal approach • Medicare provides
Slide 20: Under Consideration: Acute Heart Failure - Overview
Under Consideration: Acute Heart Failure - Overview • Opportunity: Heart failure in the U.S. is a large and growing patient population • Prevalence of heart failure grew 6-fold from 2010 – 2018 (now 6.5m patients)1,2 • A significant number of patients are hospitalized each year with acute heart fail
Slide 21: Q2 2020 Financial Results
Q2 2020 Financial Results (©ROCKWELL
Slide 22: Q2 2020: Selected Balance Sheet and Cash Flow Metrics
Q2 2020: Selected Balance Sheet and Cash Flow Metrics As of As of ($ in millions) 6/30/2020 12/31/2019 Cash, Cash Equivalents & Investments $ 40.0 $ 26.0 Long-Term Debt, net 20.8 - Working Capital 40.0 24.5 Q2 Q2 2020 2019 Cash Flow from Operations - YTD $ (16.2) $ (10.3) Total Change in Cash & Inve
Slide 23: Q2 2020: Selected Income Statement Metrics
Q2 2020 : Selected Income Statement Metrics Q2 Q2 % ($ in millions) 2020 2019 Change Net Sales $ 15.9 $ 14.8 7.1% Triferic Net Sales 0.2 0.1 100 Gross Profit 0.9 0.7 20.1 Selling & Marketing Expenses 2.0 2.2 (10.0) General & Administrative Expenses 2.9 5.5 (47.8) Research & Product Development Expen
Slide 24: Triferic International Updates
Triferic International Updates 24
Slide 25: Q&A
Q&A (© ROCKWELL MEDICAL